Alexandra Gomez-Arteaga, MD, on Orca-T as a Potential Alternative to HCT + PTCy
The Assistant Professor of Medicine at Weill Cornell Medical College discussed Orca-T cell therapy and next steps assessing it.
“This is just another way of showing that maybe we can have better control over the allograph and cell engineering, like precision immunotherapy so that we can have better control of the outcomes of these patients. I think we cannot underestimate the power of PTCy. It can be easily accessible around the world and has improved outcomes such as chronic GVHD. But this might be another way to deal with other important factors.”
Patients with hematological malignancies treated with Orca-T allogeneic cell therapy experienced a benefit in non-relapse mortality, relapse free survival (RFS), and overall survival (OS) compared with those treated with posttransplant cyclophosphamide (PTCy)-based myeloablative conditioning peripheral blood stem cell hematopoietic cell transplant, according to a retrospective analysis. Patients treated with Orca-T also had higher GvHD free survival(73% vs 54%), and RFS and OS remained high at 2 years post Orca-T. The cell therapy is being evaluated in a randomized Phase 3 registrational trial (NCT05316701).
Data from the analysis were presented at the 2024 Tandem Meetings |Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, held in San Antonio, Texas, February 21-24, 2024, by Alexandra Gomez Arteaga, MD, Assistant Professor of Medicine and Anne Moore, MD, Clinical Scholar in Hematology-Oncology, Weill Cornell Medical College.
CGTLive spoke with Arteaga to learn more about Orca-T and the components the cell therapy consists of. She shared that these findings may support Orca-T as an alternative option to hematopoietic stem cell transplant plus PTCy.
View more coverage of the 2024 Tandem Meeting now.
